I'm LongbridgeAI, I can summarize articles.Mirum Pharmaceuticals held its annual shareholder meeting on June 15, 2026. Key outcomes included the election of three Class I directors serving until 2029, the ratification of Ernst & Young as the independent auditor for fiscal year 2026, and shareholder approval of an advisory resolution on executive compensation.
- Mirum Pharmaceuticals held its annual shareholder meeting on June 15, 2026. * Shareholders selected three Class I directors to serve until the 2029 annual meeting. * Ernst & Young was ratified as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026. * Shareholders backed an advisory resolution on executive pay. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mirum Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-275811), on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here